Results 91 to 100 of about 14,264 (186)

Medication of the month. Insulin glargine (Lantus)

, 2004
peer reviewedInsulin glargine (Lantus) is a human insulin analogue produced by recombinant DNA technology and recently launched by Aventis. Modification of the human insulin molecule at position A21 and at the C-terminus of the B-chain results in the ...
Scheen, André
core  

A comparative evaluation of bioequivalence of Gan & Lee glargine U300 and Toujeo® in Chinese healthy male participants

Frontiers in Endocrinology
BackgroundTo assess the bioequivalence between Gan & Lee (GL) glargine U300 and Toujeo® regarding pharmacokinetics (PK), pharmacodynamics (PD), and safety in Chinese healthy male participants.MethodsA single-center, randomized, double-blind, single ...
Xiaoli Li, Anshun He, Bingyan Liu, Rongfang Shan, Juan Zhu, Xiaoyue Li, Tian Xie, Yue Li, Mengmeng Chen, He Su, Chaoyang Zhang, Lufeng Li, Dongmei Cheng, Juan Chen, Ying Wang, Yue Su, Yuanyuan Xu, Zhuoran Li, Huan Zhou, Wei Chen, Yuanyuan Liu   +20 more
doaj   +1 more source

Insulin detemir versus insulin glargine for type 2 diabetes mellitus

, 2011
Chronically elevated blood glucose levels are associated with significant morbidity and mortality. Many diabetes patients will eventually require insulin treatment to maintain good glycaemic control.
Hoekstra, Joost B., Swinnen, Sanne G., DeVries, J. Hans, Simon, Airin C. R., Holleman, Frits   +4 more
core   +1 more source

Nanoparticles formulations of insulin glargine: an overview [PDF]

Insulin glargine, a long-acting insulin analog, is a cornerstone in the management of diabetes mellitus. However, its therapeutic efficacy is often hindered by limitations such as variable pharmacokinetics and suboptimal bioavailability.
Satinder Kakar, Anjana Rana
core   +1 more source

Management of diabetic ketoacidosis in children: Does early insulin glargine help improve outcomes?

Journal of Diabetes
Background Rebound hyperglycemia following the resolution of diabetic ketoacidosis (DKA) is common in pediatric patients with type 1 diabetes, increasing the risk of recurrent DKA and complicating the transition to subcutaneous insulin.
Rebecca Ohman‐Hanson, G. Todd Alonso, Laura Pyle, Ryan McDonough, Mark Clements   +4 more
doaj   +1 more source

Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration

We described insulin glargine (originator) and insulin glargine-yfgn (biosimilar) treatment patterns, assessed effectiveness and safety outcomes, and identified reasons for switching back to the originator product from the biosimilar.
Diane Dong, Donald R. Miller, Anthony Au, Samantha Walczuk, Deborah Khachikian, Kelly Bryan, Cedric Salone, Xinhua Zhao, Sherrie L. Aspinall, Francesca E. Cunningham, Peter A. Glassman, Qoua Her   +11 more
core   +1 more source

Concentrated insulins: the new basal insulins

Therapeutics and Clinical Risk Management, 2016
Elizabeth M Lamos,1 Lisa M Younk,2 Stephen N Davis3 1Division of Endocrinology, Diabetes and Nutrition, 2Department of Medicine, University of Maryland School of Medicine, 3Department of Medicine, University of Maryland Medical Center, Baltimore, MD ...
Lamos EM, Younk LM, Davis SN
doaj  

Update on insulin glargine use in diabetic cats

, 2005
Glargine is a new human synthetic insulin analogue produced by recombinant DNA technology utilizing E.Coli. It differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the B-chain ...
Rand, Jacquie, Marshall, Rhett
core  

Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes

, 2007
BACKGROUND AND AIMS: Glargine improves glucose control and reduces the risk of nocturnal hypoglycemia compared with neutral protamine Hagedorn (NPH) insulin.
R. Manini, MARZOCCHI, REBECCA, MARCHESINI REGGIANI, GIULIO, G. Forlani, MOSCATIELLO, SIMONA, ZANNONI, CHIARA   +5 more
core   +1 more source

Glargine and Lispro [PDF]

Diabetes Care, 2002
Marcy A. Adlersberg, Surani Fernando, Geralyn R. Spollett, Silvio E. Inzucchi   +3 more
openaire   +1 more source